IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4402
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$22M
Robbie Knie
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy. HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-ALZ for the. treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases. HT-003 to treat inflammatory bowel diseases, as well as acne and psor
Headcount
4
HQ Base
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$HOTH Hoth Therapeutics, Inc. | 32 | 18 | 13 | 33 | - | - | -145.9% | -129.9% | - | - | - | - | 0.0% | 12.0x | $22M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
Hoth Therapeutics, Inc. (HOTH) receives a "Avoid" rating with a composite score of 31.7/100. It ranks #4402 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Pending Verification
Lagging peers — losers tend to keep underperforming
Expensive relative to fundamentals — limited margin of safety
Weak fundamentals — higher risk of value trap
High volatility — wider range of outcomes increases timing risk
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for HOTH.
View All Ratings| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 18 | 2 | +16ALPHA |
| MOMENTUM | 33 | 22 | +11ALPHA |
| VALUATION | 13 | 6 | +7ALPHA |
| INVESTMENT | 25 | 13 | +12ALPHA |
| STABILITY | 32 | 18 | +14ALPHA |
| SHORT INT | 51 | 54 | -3NEUTRAL |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROE proxy -145.9% (sector -1.9%)
GM N/A vs sector 44%, OM N/A vs sector 3%
Capital turnover N/A
Rev growth N/A, 7yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate Hoth Therapeutics, Inc. (HOTH) as Avoid with a composite score of 31.7/100 at a current price of $1.03. The stock falls in the bottom quintile, and the multi-factor weakness suggests a high probability of continued underperformance.
Hoth Therapeutics, Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 31.7/100 places it at rank #4402 in our full universe.
No Moat
High
Poor
Fair Value
Stable competitive position in a defensive sector.
Weak momentum suggests persistent institutional selling pressure.
Below-average quality raises earnings sustainability concerns.
Vulnerability to macroeconomic shocks and interest rate volatility.
Hoth Therapeutics, Inc. represents a avoid based on multi-factor quantitative performance.
Our quantitative model flags Hoth Therapeutics, Inc. with an Avoid rating, assigning a composite score of 31.7/100 and 1 out of 5 stars. Ranked #4402 of 7,333 stocks, HOTH falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
Hoth Therapeutics, Inc. registers a weak quality score of just 18/100, indicating significant profitability challenges. The company reports a return on equity of -145.9% (sector avg: -1.9%). Low quality scores are often associated with businesses in turnaround mode, early-stage growth, or structurally challenged industries.
HOTH registers a value score of just 13/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/B ratio of 1.98x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
Hoth Therapeutics, Inc.'s investment score of 25/100 suggests limited reinvestment activity. Key growth metrics include a return on assets of -129.9% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
HOTH is currently showing below-average momentum at 33/100, which may indicate weakening institutional interest or negative sentiment shifts. Revenue growth data is not currently available, while a beta of 1.27 reflects its sensitivity to broader market moves. Investors should note that declining momentum can precede further price weakness, though contrarian opportunities sometimes emerge at these levels.
HOTH's stability score of 32/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 1.27 and a debt-to-equity ratio of 12.00x (sector avg: 0.2x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
The short interest score of 51/100 for HOTH suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include above-average market sensitivity (beta: 1.27), elevated leverage (D/E: 12.00x), micro-cap liquidity risk. With a $22M market cap (micro-cap), Hoth Therapeutics, Inc. may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
Hoth Therapeutics, Inc. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #4402 of 7,333 overall (40th percentile). Key comparisons include ROE of -145.9% trailing the -1.9% sector median. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While HOTH currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Value (13) would have the largest impact on the composite score.
ROE 7579% ABOVE SECTOR MEDIAN (FAVORABLE)
Debt/Equity 5614% ABOVE SECTOR MEDIAN
Div. Yield NaN% BELOW SECTOR MEDIAN
Hoth Therapeutics, Inc. (NASDAQ: HOTH) today announced a significant expansion of its CLEER-001 Phase 2a clinical trial with the addition of Regis Clinical Research as a new enrolling site. Located in Miami, Florida, Regis joins the growing CLEER-001 investigational site network as surging patient demand outpaces capacity at existing sites — a direct reflection of the compelling early clinical results HT-001 has produced and the desperate unmet need it addresses.
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company advancing breakthrough therapies for diseases, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for "Exon Skipping of FC-Epsilon-RI-Beta and MS4A6A in the Treatment of Allergic Diseases."
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on advancing innovative therapies for cancer patients with significant unmet needs, today announced over the last several days investors have contacted the company re our exposure to digital assets such as Bitcoin , Solana and Ethereum. Hoth holds no cryptocurrency assets, and its maximum exposure never reached more than $350,000 USD over the last year. Hoth continues to execute on its HT-001 clinical tria
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on advancing innovative therapies for cancer patients with significant unmet needs, today announced positive interim results from the open-label pharmacokinetic (PK) cohort of its ongoing CLEER-001 clinical trial evaluating HT-001 in cancer patients receiving EGFR inhibitor therapy.
Shares of Peraso Inc. (NASDAQ: PRSO) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter EPS results. Peraso posted a quarterly loss of $8.52 per share, versus analysts’ estimates for a loss of $3.76 per share. The company’s quarterly sales came in at $1.83 million versus expectations of $1.70 million. Peraso shares tumbled 23.3% to $1.32 on Tuesday. Here are some other stocks moving in today's mid-day session. Gainers Ontrak, Inc. (NASDAQ: OTRK) shares climbed 197.8% to $0.5660 ahead of the company's presentation at the 36th Annual Roth Conference. Fusion Pharmaceuticals Inc. (NASDAQ: FUSN) gained 97.3% to $20.99 after the company announced agreed to be acquired by AstraZeneca. Also, Leerink Partners downgraded the stock from Outperform to Market Perform but raised its price target from $17 to $21. SCWorx Corp. (NASDAQ: WORX) gained 74% to $3.22. Spire Global, Inc. (NYSE: SPIR) climbed 50.7% to $18.50 after announcing a collaboration with NVIDIA to advance AI-driven weather prediction. Enveric Biosciences, Inc (NASDAQ: ENVB) shares climbed 43.6% to $1.5801 after the company announced that it signed two non-binding term sheets with an undisclosed biotechnology company to pursue the out-licensing of cannabinoid-COX-2 conjugate compounds for pharmaceutical and non-pharmaceutical applications for the treatment of joint diseases. Zoomcar Holdings, Inc. (NASDAQ: ZCAR) rose 33.1% to $1.57 after the company announced that it partnered with EaseMyTrip to integrate its cars within the travel platform. Hoth Therapeutics, Inc. (NASDAQ: HOTH) surged 32% to $1.51 after the company announced pre-clinical research showcasing the potential of HT-ALZ in Alzheimer's disease. Enliven Therapeutics, Inc. (NASDAQ: ELVN) gained 27.2% to $16.09. The company announced a $90 million private placement financing and provided pipeline updates. National CineMedia, Inc. (NASDAQ: NCMI) gained 25.5% to $5.30 after the company posted upbeat results for its fourth quarter and disclosed a new $100 million share repurchase program. The company said it sees first-quarter total revenue of $34.5 million to $35.5 million. Alignment Healthcare, Inc. (NASDAQ: ALHC) gained 17.7% to $5.50. Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) rose 15% to $43.63 ...
Above 50MA
37.18%
Net New Highs
+51081